Assessing the effectiveness of camrelizumab plus anti-angiogenesis drug for the treatment of advanced liver cancer: a single‑center retrospective study
Based on real-world data, individuals with intermediate and advanced primary liver cancer undergoing systemic therapy may benefit from camrelizumab combined with anti-angiogenic drugs.
Authors
- Fang Lü (ORCID: https://orcid.org/0000-0002-0570-7801)
- Fan-rong Wu (ORCID: https://orcid.org/0000-0002-8079-7595)
Institutions
- Anhui Medical University (CN)
- 117th Hospital of People's Liberation Army (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- Immunopharmacology and Immunotoxicology
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1080/08923973.2025.2513481
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China